How International Trade Policy Can Boost American Innovation

October 16, 2026
1792184601942

October is Intellectual Property Month, a time to recognize how IP rights power the American innovation ecosystem that makes the U.S. a global leader in fields like biotechnology, pharmaceuticals, and artificial intelligence.

However, IP protections at home mean little if foreign governments can undermine the economic rewards they are designed to secure. U.S. officials can,  and should, examine how our trading partners’ policies weaken incentives to invest in innovation — and use our economic leverage to encourage foreign governments to enact meaningful reforms.

Take the life sciences sector, for example. Developing new medical therapies can require years of research and billions of dollars of capital. Investors accept those risks because IP protections on successful discoveries mean they can earn sufficient returns.

But there’s a catch. Foreign governments, like Germany and Japan, systematically drive prices below market levels, among other unfair practices that let them essentially free-ride on American innovation. That limits expected returns on successful treatments — and in turn makes investment in pharmaceutical research less attractive.

There is a path forward. Earlier this year, the United States Trade Representative released the annual Special 301 Report and, for the first time, dedicated a standalone section to Intellectual Property and Standards.

The report offers several solutions that will protect American intellectual property on the global stage:

  • USTR must secure specific bilateral commitments that preserve access to injunctive relief for standard-essential patent (SEP) holders consistent with Fair, Reasonable, and Non-Discriminatory (FRAND) principles.
  • U.S. agencies, such as the USPTO, should ensure that domestic policy positions on SEPs and injunctive relief reinforce the trade posture outlined in the Special 301 Report.
  • Congress should pass the RESTORE Act, a bipartisan bill that would reinstitute a statutory rebuttable presumption of injunctive relief in cases where a U.S. court has issued a final finding of infringement.

That’s not all. USTR ought to initiate Section 301 investigations where warranted.

Earlier this year, USTR launched a Section 301 investigation into Germany’s unfair pharmaceutical pricing policies. Other countries, including some of our largest trading partners, like Canada, Japan, and South Korea, are paying close attention. The investigation sends a clear message that the United States expects our wealthy allies to contribute their fair share toward American innovation.

If USTR succeeds in securing meaningful reforms in Germany, it will send a powerful signal that the United States is willing to use its trade leverage to protect American intellectual property and stand up for the workers, businesses, and investors driving medical innovation.

Learn more: Read our takeaways from the Special 301 Report here, and former Deputy USTR Jeff Gerrish’s op-ed for Fox News on the importance of further Section 301 investigations here.

Scroll to Top